MedReleaf Corp. (TSX:LEAF) announced this morning that the company has entered into an partnership with Cannamedical Pharma GMBH to supply medical, MedReleaf branded, cannabis products to distribute to a collection of 1,800 pharmacies in Germany.
MedReleaf will begin sending product to Cannamedical Pharma GMBH once the company’s European Medical Agency Good Manufacturing Practices (“GMP”) certification and export permit from Health Canada are obtained in the next coming weeks.
MedReleaf Corporation will export five of its “premium stain” collections which will significantly improve upon the consistency of cannabis products distributed in Germany. Germany will rely on cannabis exports to meet the growing demand of products in the country.
“Federally legal markets for cannabis outside Canada are by and large focused on medical applications. This plays to MedReleaf’s core strengths in R&D, innovation, quality control, and pharmaceutical grade standards,” said Neil Closner, President and CEO. “Medical cannabis in Germany has been in short supply and Cannamedical is an ideal partner to bring MedReleaf’s premium cannabis products into Germany as one of Europe’s leading cannabis distributors with shared values on patient-centricity, a proven track record, and a growing network of 1,800 pharmacies.”